What Tecnonuclear does

Tecnonuclear S.A. is an Argentine radiopharmaceutical manufacturer founded in 1992 and headquartered in Buenos Aires, specializing in nuclear medicine products for diagnostic imaging and therapy. The company operates a manufacturing plant in Buenos Aires and supplies more than 200 healthcare institutions across Argentina, with exports to Latin America and North America. Its product portfolio spans four core categories: SPECT radiopharmaceuticals and 99Mo/99mTc radionuclide generators (with over 20 cold kit products for bone, cardiac, renal, hepatic, and neurological imaging); PET radiopharmaceuticals (18F-FDG, 18F-Choline, 18F-Dopa, 18F-FLT, 18F-PSMA, 68Ga-PSMA, and 68Ga-DOTATOC); MRI contrast media (gadolinium-based GADO-TEC); and therapeutic radiopharmaceuticals (Iodine-131 capsules and solutions, EDTMP-153Sm for bone metastasis palliation, and 177Lu-DOTA-TATE/LUNET for neuroendocrine tumor treatment). The company also distributes parent-group Eckert & Ziegler isotope products through its regional channel.

Tecnonuclear's business model is direct B2B sales to healthcare institutions, with bespoke pricing delivered via sales executives (no public price list). The GTM motion is sales-led: a specialized sales team handles personalized consultation, quoting, and product guidance, supported by direct phone, email, WhatsApp, and a business-hours contact center. Orders for generators require advance scheduling (15 days domestically, 2 weeks for export), reflecting the time-sensitive nature of short-lived radioactive products. The company maintains a bilingual Spanish/English website, a newsletter, and ongoing training partnerships with AABYMN (Argentinian Association of Nuclear Medicine and Biology professionals). Distribution is direct-to-institution domestically and via authorized logistics partners for international markets, with all cross-border shipments subject to destination-country nuclear regulatory and health authority approvals.

In 2022, Tecnonuclear became a wholly-owned subsidiary of Eckert & Ziegler, a German-based international isotope technology group. The E&Z integration provides Tecnonuclear access to global manufacturing platforms, technology resources, and distribution networks across facilities in Germany, France, Spain, the United States, Brazil, and China, while preserving its regional leadership position in the Argentine and LATAM nuclear medicine market. The company has 101-250 employees and operates as a private Argentine corporation.

Name

Tecnonuclear

Legal name

Tecnonuclear S.A.

Website

https://tecnonuclear.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

101–250 employees

Short description

Tecnonuclear is an Argentine radiopharmaceutical manufacturer producing SPECT, PET, MRI contrast, and therapeutic nuclear medicine products for hospitals, clinics, and diagnostic imaging centers. Founded in 1992 and now an Eckert & Ziegler subsidiary, it supplies 200+ Argentine healthcare institutions and exports across Latin America.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Radiopharmaceutical & Nuclear Medicine Distributors (HLAIAJAI), Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)

Keywords

• Nuclear medicine products
• Radiopharmaceutical manufacturing
• Diagnostic imaging agents
• Radionuclide generators
• Theragnostic therapy

Headquarters

HQ city

Buenos Aires

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Radiopharmaceutical Products: Production and sale of radiopharmaceuticals for nuclear medicine including SPECT, PET, and therapeutic products. These are short-lived radioactive products that require precise logistics and scheduling, sold to healthcare institutions.
2. Radionuclide Generators: 99Mo/99mTc generator systems sold to healthcare facilities and exported to Latin American and North American markets. Generators are calibrated products with defined activity levels requiring advance ordering (15 days for domestic, 2 weeks for export).
3. Cold Kits / Reagent Kits: Non-radioactive reagent kits (cold kits) for preparation of technetium-99m radiopharmaceuticals, including bone imaging, cardiac, renal, hepatic, and neurological diagnostic agents. Sold in kit formats with multiple vials.
4. MRI Contrast Agents: Gadolinium-based paramagnetic contrast media (GADO-TEC) for magnetic resonance imaging, sold in box quantities to healthcare providers.
5. Therapeutic Radiopharmaceuticals: Therapeutic products including Iodine-131 capsules and solutions, EDTMP-153Sm for bone metastasis pain palliation, and 177Lu-DOTA-TATE for neuroendocrine tumor treatment. Requires advance scheduling and subject to availability.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Tecnonuclear manufactures and distributes radiopharmaceuticals and radionuclide generators for nuclear medicine. Its product portfolio covers SPECT imaging kits (99mTc-based bone, cardiac, renal, hepatic, and neurological agents), PET tracers (18F-FDG, PSMA agents, DOTATOC, choline, DOPA, FLT), gadolinium-based MRI contrast media, and therapeutic radiopharmaceuticals (I-131, EDTMP-153Sm, 177Lu-DOTA-TATE). Products are produced at its Buenos Aires facility, supplied to more than 200 Argentine health institutions, and exported to Latin America and North America.

Product overview

Tecnonuclear is an Argentine radiopharmaceutical company with over 30 years of experience, now part of Eckert & Ziegler, offering a comprehensive portfolio of nuclear medicine products. The product range includes: SPECT radiopharmaceuticals and 99Mo/99mTc generators (23 products); PET products including 18F-FDG, 18F-Choline, 18F-Dopa, 18F-FLT, FLUPROS (18F-PSMA), GANET (68Ga-DOTATOC), and GAPROS (68Ga-PSMA); MRI contrast media (GADO-TEC with gadolinium); and therapeutic products including IODO-131 capsules/solutions, EDTMP-153Sm for bone metastases palliation, and LUNET (177Lu-DOTA-TATE) for neuroendocrine tumors. The company also distributes E&Z isotope products and provides generator elution accessories. These products serve nuclear medicine departments, hospitals, and diagnostic imaging centers for diagnostic imaging (SPECT, PET, MRI) and targeted radiopharmaceutical therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• SPECT Radiopharmaceutical Products Single photon emission computed tomography (SPECT) radiopharmaceuticals including reagent kits and ready-to-use solutions for nuclear medicine diagnostic imaging. BONE-TEC (MDP) for skeletal imaging, MYOCARDIUM-TEC (MIBI) for cardiac perfusion, KIDNEY-TEC (DMSA) for renal cortical imaging, NEFRO-TEC (DTPA) for renal function, HEPATO-TEC for liver imaging, BILIO-TEC for hepatobiliary imaging, NEURO-TEC (ECD) for cerebral perfusion, DOPA-TEC (Trodat-1) for Parkinson's disease diagnosis, NANO-TEC for sentinel lymph node, INFECTION-TEC for infection imaging, TIN-TEC for bone imaging and acute myocardial infarction, MAA for pulmonary perfusion, RENO-TEC (MAG-3) for renal tubular function, and OSTEO-TEC (HMDP) for skeletal imaging. Sold to healthcare institutions for nuclear medicine procedures.
• PET Radiopharmaceutical Products Positron emission tomography (PET) radiopharmaceuticals for oncology and neurology diagnostics. Fluordeoxiglucosa FDG (18F-FDG) for cancer, cardiac and neurology imaging; FLUPROS (18F-PSMA) for prostate cancer detection; GAPROS (68Ga-PSMA) for prostate cancer imaging; GANET (68Ga-DOTATOC) for neuroendocrine tumors; 18F-Colina (FCH) for prostate cancer metastasis and hepatocellular carcinoma; 18F-DOPA for Parkinson's disease and neuroendocrine tumors; 18F-FLT for lymphoma, melanoma, lung and breast cancer staging. Sold to healthcare institutions with nuclear medicine departments.
• GADO-TEC MRI Contrast Media Gadolinium-based paramagnetic contrast medium (gadopentetate dimeglumine) for intravenous use in magnetic resonance imaging. Provides high contrast in areas with insufficient blood-brain barrier and altered blood flow or modified extracellular areas. Indicated for adults and children over two years of age. Sold in box quantities (10 vials) to healthcare providers.
• Therapeutic Radiopharmaceuticals Therapeutic radiopharmaceuticals including IODO-131 (I-131) capsules and solutions for thyroid disease treatment (Graves' disease, toxic goiter, thyroid carcinoma), EDTMP-153Sm (Samarium-153) for rapid palliation of bone pain from osteoblastic bone metastases, and LUNET (177Lu-DOTA-TATE) radioligand therapy for advanced well-differentiated gastrointestinal neuroendocrine tumors. Sold to healthcare institutions. Requires advance scheduling and subject to availability.
• 99Mo/99mTc Radionuclide Generator Dry column generator system for obtaining sterile, pyrogen-free solutions of sodium pertechnetate (99mTc), suitable for radiopharmaceutical kit labeling or direct intravenous administration. Available in multiple activity presentations from 100mCi to 2000mCi. Sold to healthcare facilities and exported to Latin American and North American markets. Domestic orders require 15 days advance notice; international orders require 2 weeks advance notice.
• E&Z Isotope Products Distribution Isotope products from Eckert & Ziegler parent company, available through Tecnonuclear's distribution network across Latin America. Sold to healthcare institutions and research facilities.
• Generator Elution Accessories (FRASCOS Kits) Generator elution kits including FRASCOS ELUCION (kit with 10 vacuum vials and 10 vials with physiological solution), FRASCOS FISIOLO (physiological solution vials), and FRASCOS VACIO (sterile vacuum vials) for 99mTc generator elution procedures. Sold to healthcare institutions using Tecnonuclear generators.

Quantifiable outcome

• Supplies 200+ health institutions in Argentina
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• Eckert & ZieglercoreStrategic or Co-development Partner · 1 January 2022In 2022, Tecnonuclear integrated into the international Eckert & Ziegler (E&Z) group, a global leader in isotope technology and radiopharmaceutical solutions. This integration strengthened Tecnonuclear's global presence and commitment to scientific excellence, safety, and continuous development. As part of E&Z, Tecnonuclear expands its international reach and enhances its capacity for innovation in radiopharmaceuticals for SPECT, PET, and theragnostics. The E&Z partnership provides access to global infrastructure, technology platforms, and distribution networks across multiple countries.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• GE Healthcare: GE Healthcare operates a major radiopharmaceutical and PET tracer business (including 18F-FDG and 18F-PSMA via its Pharmaceutical Diagnostics segment) alongside its dominant imaging equipment franchise, making it a broad incumbent with overlapping product lines.
• Novartis (Advanced Accelerator Applications): Novartis, through its AAA subsidiary, markets Lutathera (177Lu-DOTATATE) and Pluvicto (177Lu-PSMA-617), directly competing with Tecnonuclear's LUNET and PSMA agents. As a major pharma incumbent with heavily invested theranostic franchises, it sets the competitive benchmark in therapeutic radiopharmaceuticals.
• Bracco Imaging: Bracco is a global contrast media and imaging diagnostics company that produces MRI contrast agents (including gadolinium-based agents competing with GADO-TEC) and other diagnostic imaging products, comparable as a broader incumbent in medical imaging diagnostics.
• Eckert & Ziegler (E&Z): E&Z is Tecnonuclear's German parent company and a global leader in isotope technology and radiopharmaceutical components, including isotope products, radiopharma services, and radiation sources. It is technically the parent, but as a broader conglomerate with adjacent radiopharma activities it serves as a comparable broad incumbent.

Regional players

• Cardinal Health (Nuclear & Precision Health Solutions): Cardinal Health operates one of the largest US radiopharma distribution networks, similar in distribution model to Tecnonuclear's domestic network of 200+ health institutions, though focused primarily on the US market.
• PharmaLogic Holdings: PharmaLogic is a CDMO and radiopharmaceutical distributor operating in the US and Canada with a portfolio of SPECT/PET agents and theranostics. Its regional focus and product overlap make it a relevant regional peer for Tecnonuclear's distribution-led LATAM model.

Emerging players

• Sirtex Medical: Sirtex is a specialist in therapeutic radiopharmaceuticals, primarily known for SIR-Spheres Y-90 microspheres for liver cancer, with a growing pipeline in Lu-177-based therapies — overlapping with Tecnonuclear's therapeutic segment (Sm-153 EDTMP and Lu-177 DOTA-TATE).
• Telix Pharmaceuticals: Telix is a rapidly growing radiopharma company with approved PSMA-PET imaging agent Illuccix and a developing therapeutic pipeline, competing directly with Tecnonuclear's FLUPROS/GAPROS PSMA tracers and emerging therapy plans.

Direct peers

• Curium Pharma: Curium is a global radiopharmaceutical manufacturer producing SPECT generators (99Mo/99mTc), PET tracers, and therapeutic radiopharmaceuticals across multiple geographies, directly comparable to Tecnonuclear's full-spectrum portfolio.
• Lantheus Holdings: Lantheus is a leading US-based radiopharmaceutical company specializing in SPECT (99Mo/99mTc generators, Neurolite, Xenon) and PET (Pylarify/18F-DCFPyL PSMA) agents, and is one of the most direct global competitors to Tecnonuclear's SPECT/PET portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tecnonuclear